ArticleCancer discovery2017
Activating
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 239 papers.
0numbers the graph read from it
0cells of the map it votes in
239citing papers in PubMed
27.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
239 citing papers in PubMed, 364 citations in OpenAlex.
- ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.Nature communications · 2026Trial
- Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.Breast cancer research : BCR · 2025Trial
- A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.Breast cancer research : BCR · 2025Trial
- AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.Nature communications · 2022Trial
- Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.The Lancet. Oncology · 2020Trial
- Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment.The Journal of clinical investigation · 2026Review
- FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation.Journal of medicinal chemistry · 2026Article
- Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation.Angewandte Chemie (International ed. in English) · 2026Article
- Steroid receptor coactivators: from basic research to translational opportunities.Endocrine reviews · 2026Review
- Nucleic sexual hormone receptor signaling pathways in breast cancer: function regulation, crosstalk, and therapeutic implications.NPJ precision oncology · 2026Review
- Distinct 2-phenylimidazo[1,2-iScience · 2026Article
- DOCTER: a genetically encoded switchable protein module for ERα-mediated transcriptional regulation.Gene therapy · 2026Article
- Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation.NPJ breast cancer · 2026Article
- The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.Molecular cancer therapeutics · 2026Article
- A Novel Sensitive Technique to DetectCancer innovation · 2026Article
- The role of the SLC25A15 transporter in the formation of liver metastasis in ESR1-mutated breast cancer.Oncogene · 2026Article
- Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Breast cancer research : BCR · 2026Article
179 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 3 countries.
Weiyi ToyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Hazel WeirAstraZeneca, iMED Oncology, Cambridge, UK.
Pedram RazaviHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Mandy LawsonAstraZeneca, iMED Oncology, Cambridge, UK.
Anne U GoeppertAstraZeneca, Discovery Sciences, IMED Biotech Unit, Cambridge, UK.
Anne Marie MazzolaAstraZeneca, iMED Oncology, Waltham, Massachusetts.
Aaron SmithAstraZeneca, iMED Oncology, Cambridge, UK.
Joanne WilsonAstraZeneca, iMED Oncology, Cambridge, UK.
Christopher MorrowAstraZeneca, iMED Oncology, Cambridge, UK.
Wai Lin WongAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa De StanchinaAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Kathryn E CarlsonDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois.
Teresa S MartinDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois.
Sharmeen UddinHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Zhiqiang LiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sean FanningBen May Department for Cancer Research, University of Chicago, Chicago, Illinois.
John A KatzenellenbogenDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois.
Geoffrey GreeneBen May Department for Cancer Research, University of Chicago, Chicago, Illinois.
José BaselgaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. chandars@mskcc.org.
Memorial Sloan Kettering Cancer Center · USIntegrated Medicines (United Kingdom) · GBUniversity of Illinois Urbana-Champaign · USMay Institute · USAstraZeneca (Japan) · JPMassachusetts Medical Society · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTherapeutic approaches to ER mutant breast cancerR01CA204999 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2017 to 2021
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204999
Abstract
Recent studies have identified somatic
Indexed as
AnimalsAntineoplastic Agents, HormonalBreast NeoplasmsCinnamatesEstradiolEstrogen Receptor alphaEstrogen Receptor AntagonistsFemaleFulvestrantHumansIndolesMCF-7 CellsMice, Inbred BALB CMice, NudeMutationProtein DomainsAntineoplastic Agents, HormonalAZD9496CinnamatesESR1 protein, humanEstradiolEstrogen Receptor alphaEstrogen Receptor AntagonistsFulvestrantIndoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.